Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids

Physician and Sportsmedicine

Volumn 40, Issue 4, 2012, Pages 12-20

  Stanos, Steven ^a,b  

^a REHABILITATION INSTITUTE OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Classwide REMS; Extended release opioid; Long acting opioid; Opioid abuse; Opioid misuse; REMS

Indexed keywords

ALCOHOL; BUPRENORPHINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE; OPIATE; OXYCODONE; OXYMORPHONE; SULFANILAMIDE; THALIDOMIDE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; DEATH; DRUG CAPSULE; DRUG FORMULATION; DRUG LABELING; DRUG LEGISLATION; DRUG OVERDOSE; DRUG PROGRAM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; OPIATE ADDICTION; PAIN; PATIENT COUNSELING; PATIENT EDUCATION; PRESCRIPTION; RISK MANAGEMENT; TABLET; TRAINING; UNITED STATES; CHEMISTRY; DELAYED RELEASE FORMULATION; INCIDENCE; LEGAL ASPECT; METHODOLOGY; ORGANIZATION AND MANAGEMENT; POSTMARKETING SURVEILLANCE; REVIEW; RISK ASSESSMENT;

ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HUMANS; INCIDENCE; LEGISLATION, DRUG; OPIOID-RELATED DISORDERS; PAIN; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; RISK MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

MLCS; MLOWN;

EID: 84874519668     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2012.11.1975     Document Type: Article

References (55)

1. Governale L. Outpatient presciption opioid utilization in the US, years 2000-2009. US Food and Drug Administration Drug Safety and Risk Management Advisory Committee. July 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/drugsafetyandriskmanagementadvisorycommittee/ucm220950.pdf. Accessed June 25, 2012.
2. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004;109(3):514-519.
3. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain. 2006;7(4):225-235.
4. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11(2 suppl):S63-S88.
5. US Department of Health and Human Services, Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. July 2010. http://www.cdc.gov/homeandrecreationalsafety/pdf/poison-issue-brief.pdf. Accessed June 25, 2012.
6. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2010 National Survey on Drug Use and Health: Summary of national findings. Rockville, MD: Office of Applied Studies; 2011. NSDUH Series H-38 A, HHS Publication No. SMA 11-4658. http://www.samhsa.gov/data/nsduh/2k10nsduh/2k10results.pdf. Accessed June 26, 2012.
7. Chabal C, Erjavec MK, Jacobson L, Mariano A, Chaney E. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin J Pain. 1997;13(2):150-155.
8. Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97(4):1097-1102.
9. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444-459.
10. Manchikanti L, Pampati V, Damron KS, Fellows B, Barnhill RC, Beyer CD. Prevalence of opioid abuse in interventional pain medicine practice settings: a randomized clinical evaluation. Pain Physician. 2001;4(4):358-365.
11. United States Government Accountability Office. Prescription Pain Reliever Abuse: Agencies Have Begun Coordinating Education Efforts, but Need to Assess Effectiveness. Washington, DC; December 2011. GAO-12-115. http://www.gao.gov/assets/590/587301.pdf. Accessed July 12, 2012.
12. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
13. Fishman SM. Responsible Opioid Prescribing: A Physician's Guide. Washington, DC: Waterford Life Sciences; 2007.
14. Joint Meeting of the Anesthetic and life support drugs advisory committee and the drug safety and risk management advisory committee. Background package: Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics. 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anestheticandlifesupportdrugsadvisorycommittee/ucm217510.pdf. Accessed June 25, 2012.
15. US Department of Health and Human Services, US Food and Drug Administration. Questions and answers: FDA requires a risk evaluation and mitigation strategy (REMS) for long-acting and extendedrelease opioids. Updated April 19, 2011. http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm251752.htm. Accessed June 25, 2012.
16. Reder RF, Oshlack B, Miotto JB, Benziger DD, Kaiko RF. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther. 1996;18(1):95-105.
17. Shram MJ, Sathyan G, Khanna S, et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010;30(1):25-33.
18. Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164(11):1750-1756.
19. Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004; 23(4):1-9.
20. US Department of Health and Human Services, US Food and Drug Administration. Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). Published July 2012. http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm311290.pdf. Accessed July 13, 2012.
21. US Department of Health and Human Services, US Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm111350.htm. Updated July 9, 2012. Accessed July 13, 2012.
22. Office of National Drug Control Policy. Epidemic: responding to America's prescription drug abuse crisis. http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan_0.pdf. Accessed June 25, 2012.
23. Pure Food and Drug Act (1906). United States Statutes at Large (59th Congress, Session 1, Chapter 3915; cited as 34 US Stats. 768) In: North M, ed. Medicine in the Americas: Historical Works. Bethesda, MD: National Library of Medicine; 2004. http://www.ncbi.nlm.nih.gov/books/nbk22116. Accessed June 25, 2012.
24. Barkan ID. Industry invites regulation: the passage of the Pure Food and Drug Act of 1906. Am J Public Health. 1985;75:18-26.
25. Wilbert MI. The elimination of the nostrum traffic an evident duty of american physicians. Cal State J Med. 1906;4(3):84-86.
26. Kalant H. Opium revisited: a brief review of its nature, composition, non-medical use and relative risks. Addiction. 1997;92(3):267-277.
27. US Department of Health and Human Services, US Food and Drug Administration. Significant dates in US food and drug law history. Updated October 14, 2010. http://www.fda.gov/aboutfda/whatwedo/history/milestones/ucm128305.htm. Accessed June 25, 2012.
28. US Department of Health and Human Services, US Food and Drug Administration. Guidance: Drug Safety Information-FDA's Communication to the Public. Center for Drug Evaluation and Research (CDER). March 2007. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072281.pdf. Accessed July 12, 2012.
29. US Department of Health and Human Services, US Food and Drug Administration. Guidance for industry: format and content of proposed Risk Evaluation and Mitigation Strategies (REMS), REMS assessments, and proposed REMS modifications. Rockville, MD: US Department of Health and Human Services; 2009. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm184128.pdf. Accessed June 25, 2012.
30. US Department of Health and Human Services, US Food and Drug Administration. Guidance for industry: Development and use of Risk Minimization Action Plans. Rockville, MD: US Department of Health and Human Services; 2005. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126830.pdf. Accessed June 25, 2012.
31. US Department of Health and Human Services, US Food and Drug Administration. Food and Drug Administration Amendments Act (FDAAA) of 2007. Updated December 2, 2011. http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfd cact/significantamendmentstothefdcact/foodanddrugadministrationamendmentsactof2007/default.htm. Accessed June 25, 2012.
32. Celgene Corporation. Thalomid risk evaluation and mitigation strategies: System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.). Summit, NJ: Celgene Corporation; 2010.
33. The iPLEDGE Program. The Guide to Best Practices for the iPLEDGE Program. https://www.ipledgeprogram.com/documents/guide%20to%20best%20practices%20-%20ipledge%20program.pdf. Updated April 2012. Accessed June 25, 2012.
34. Exalgo approval letter. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/021217orig1s002ltr.pdf. Published July 9, 2012. Accessed August 1, 2012.
35. Oxycontin approval letter. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022272orig1s010ltr.pdf. Published July 9, 2012. Accessed July 17, 2012.
36. Butrans approval letter. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/021306orig1s008ltr.pdf. Published July 9, 2012. Accessed August 1, 2012.
37. US Department of Health and Human Services, US Food and Drug Administration. List of long-acting and extended-release opioid products required to have an opioid REMS. http://www.fda.gov/drugs/drugsafety/Informationbydrugclass/ucm251735.htm. Updated July 9, 2012. Accessed July 13, 2012.
38. US Department of Health and Human Services, US Food and Drug Administration. Blueprint for prescriber continuing education program. July 9, 2012. http://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed August 12, 2012.
39. US Department of Health and Human Services, US Food and Drug Administration. FDA opioid REMS meeting with industry. May 16, 2011, Silver Spring, MD. http://www.fda.gov/drugs/drugsafety/Informationbydrugclass/ucm258184.htm. Accessed August 1, 2012.
40. Smith H, Fine P, Passik S. Opioid Risk Management: Tools and Tips. New York, NY: Oxford University Press; 2009.
41. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112.
42. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671-681.
43. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360-372.
44. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004;26(4):552-561.
45. Webster LR, Webster RM. Predicting aberrant behaviors in opioidtreated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.
46. Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007; 37(4):301-314.
47. Bartholomaeus JH, Arkenau-Maric E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9(8):879-891.
48. Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediateand extended-release oxycodone. Pain Med. 2011;12(4):618-631.
49. Benedek IH, Jobes J, Xiang Q, Fiske WD. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther. 2011;5:455-463.
50. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11-18.
51. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007;32(3):562-575.
52. Alliance of States with Prescription Monitoring Programs. Prescription Monitoring Frequently Asked Questions. http://www.pmpalliance.org/content/prescription-monitoring-frequently-asked-questions-faq. Accessed June 25, 2012.
53. Alliance of States with Prescription Drug Monitoring Programs. Status of Prescription Drug Monitoring Programs (PMPs). http://www.pmpalliance.org/pdf/pmpstatusmap2012.pdf. Updated June 13, 2012. Accessed June 25, 2012.
54. US Department of Justice, Drug Enforcement Administration. National Take Back Initiative. http://www.deadiversion.usdoj.gov/drug_disposal/takeback. Accessed June 25, 2012.
55. US Department of Health and Human Services, US Food and Drug Administration. Medication disposal: questions and answers. http://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/ensuringsafeuseofmedicine/safedisposalofmedicines/ucm186188.htm. Updated October 14, 2009. Accessed June 25, 2012.